Gilead Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Gilead Sciences's estimated annual revenue is currently $27.5B per year.
- Gilead Sciences's estimated revenue per employee is $1,562,429
- Gilead Sciences's total funding is $85.3M.
- Gilead Sciences's current valuation is $90B. (January 2022)
Employee Data
- Gilead Sciences has 17588 Employees.
- Gilead Sciences grew their employee count by 2% last year.
Gilead Sciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, Design Studio | Reveal Email/Phone |
2 | Chief Pilot | Reveal Email/Phone |
3 | Chief Staff, Biologics Manufacturing and Site Operations | Reveal Email/Phone |
4 | Executive Director, Strategic and Key Accounts | Reveal Email/Phone |
5 | Administrative Coordinator to VP | Reveal Email/Phone |
6 | Executive Director, Sales Analytics & Operations | Reveal Email/Phone |
7 | Executive Director, National Accounts & Market Access | Reveal Email/Phone |
8 | Executive Director, Oncology Sales | Reveal Email/Phone |
9 | Executive Assistant to Regional VP | Reveal Email/Phone |
10 | CFO | Reveal Email/Phone |
Gilead Sciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $69340M | 107310 | 4% | N/A | $308.4B |
#2 | $25770M | 40280 | 10% | $68M | $132.6B |
#3 | $55170M | 56697 | 5% | $10.9M | $240.2B |
What Is Gilead Sciences?
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has five marketed products and focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.
keywords:N/A
$85.3M
Total Funding
17588
Number of Employees
$27.5B
Revenue (est)
2%
Employee Growth %
$90B
Valuation
N/A
Accelerator
Gilead Sciences News
Often in court and on the defense, Johnson & Johnson is playing the plaintiff role in a lawsuit aimed at distributors and pharmacies who...
During the European Congress of Clinical Microbiology & Infectious Diseases, Gilead Sciences presented data that showed its COVID-19 antiviral Veklury...
The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead...
By Maria Armental Gilead Sciences Inc.'s third-quarter results beat Wall Street targets, helped by $1.9 billion in sales of its antiviral drug remdesivir that is used to treat hospitalized Covid-19 patients. Here's what you need to know: PROFIT: Third-quarter profit rose to $2.59 billion from ...
Foster City, Calif. - Gilead announced it will not pursue a marketing authorization for Descovy(emtricitabine 200 mg/tenofovir alafenamide 25 mg) for pre-exposure prophylaxis (PrEP) in the European Union (EU) at this time. Conversations with healthcare professionals, payers and other stakeholder ...
Other Companies in Foster City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $24110M | 26204 | 3% | N/A |